FeaturedMedia Release
Investigational New Drug application filed with FDA
Race Oncology has announced the US Food and Drug Administration has received its Investigational New Drug (IND) application for the company’s cancer drug Bisantrene. The IND application is a
- Posted by: Race Oncology
FeaturedMedia Release
Principal Investigator appointed for Bisantrene trial
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal Investigator for the US registration trial for Bisantrene. Roland B. Walter, MD PhD MS, is a leading
- Posted by: Race Oncology
FeaturedMedia Release
Race appoints leading haematologist to support Bisantrene
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor Borje Andersson from the M.D. Anderson Cancer Research Center in Houston, Texas. Under the initial
- Posted by: Race Oncology
FeaturedMedia Release
Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP) distribution and sales agreement in Israel with TrueMed Ltd. According to Race, TrueMed is a
- Posted by: Race Oncology
FeaturedMedia Release
Race appoints BioSynergy to pursue Bisantrene licensing
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy Partners LLC (BioSynergy) to pursue licensing and other deals for Bisantrene (the ‘Agreement’).
- Posted by: Race Oncology
Media Release
Compelling value upside for Race
A new report by Independent Investment Research suggests that Australian biotech Race Oncology (ASX:RAC) is significantly undervalued.
- Posted by: Race Oncology
Featured
Finance News Network interviews CEO Peter Molloy
CEO Peter Molloy spoke with Finance News Network about Bisantrene and Race Oncology’s future prospects.
- Posted by: Race Oncology